https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20977 TM), approved by the U.S. Food and Drug Administration for the treatment of adult basal cell carcinoma. In this perspective we outline the current state of Hh pathway inhibitors with a particular focus on potential limitations of upstream Hh pathway inhibition in relation to resistance mutations and crosstalk pathways. Together, these limitations indicate that inhibition of downstream components, specifically the Gli family of transcription factors, may represent a next generation approach to suppress tumours associated with aberrant Hh pathway signalling. © 2014 The Royal Society of Chemistry.]]> Mon 19 Aug 2024 16:07:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28064 Mon 19 Aug 2024 14:51:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25063 Fri 16 Aug 2024 16:59:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19862 t-butyl based palladium catalyst CatCart™ FC1032™. Deactivated aryl bromides and activated aryl chlorides were cross-coupled with 5-formyl-2-furanylboronic in the presence of (Bu)₄N⁺OAc⁻ using the bis-triphenylphosphine CatCart™ PdCl₂(PPh₃)₂-DVB. Initial evidence indicates the latter method may serve as a universal approach to conduct Suzuki cross-couplings with the protocol successfully employed in the synthesis of the current gold standard Hedgehog pathway inhibitor LDE225.]]> Fri 16 Aug 2024 15:06:59 AEST ]]>